A Phase 3, Double-Blind, Multicenter, Multinational, Randomized, Placebo-Controlled Trial Evaluating Aztreonam Lysinate for Inhalation in Cystic Fibrosis Patients With Pulmonary Pseudomonas Aeruginosa (AIR-CF1).
Phase of Trial: Phase III
Latest Information Update: 20 Apr 2011
At a glance
- Drugs Aztreonam (Primary)
- Indications Cystic fibrosis; Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections
- Focus Registrational; Therapeutic Use
- Acronyms AIR-CF1
- Sponsors Corus Pharma; Gilead Sciences
- 05 May 2009 Results have been reported in Chest.
- 22 Dec 2006 New trial record.